Participate in Research

Preventing infections in patients who have chronic lymphocytic leukemia (CLL)
Protocol: STUDY00006499
Full Title
DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PROSPECTIVE PHASE III STUDY EVALUATING EFFICACY AND SAFETY OF PANZYGA IN PRIMARY INFECTION PROPHYLAXIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (???PRO-SID??? study)
Description
The University at Buffalo (UB) Department of Medicine is looking for adults who have chronic lymphocytic leukemia (CLL) for a study to investigate if Panzyga (the study drug) can help with preventing infections.

The immune system is a bodily system that protects the body from foreign substances, infection agents, cells, and tissues. When immune system does not work properly, it´s called immunodeficiency. This can be caused for example by hematological malignancies (forms of cancer that begin in the cells of blood-forming tissue, such as the bone marrow, or in the cells of the immune system) like chronic lymphocytic leukemia (CLL). That´s why patients with CLL are at major risk for severe infections.

Panzyga is a solution for intravenous administration, which contains human antibodies also called immunoglobulins. Your participation in this clinical study could last for up to 60 weeks (Screening up to 8 weeks, Treatment period and follow-up Visit 52 weeks).
Compensation: No
Eligibility
Adults 18 years or older Have been diagnosed with CLL and Hypogammaglobulinemia
Age Group: Adults
Principal Investigator: Robert Setlik
Contact(s)
Gabriel Rubio
grubio@buffalo.edu
Want to Learn More?

Let us know how the study team can reach you. If you do not hear back within 2 business days, then reach out to the study team directly at the contact information above and someone will assist you.

Your information will be shared only with the research study team and administrative staff for recruitment and will remain confidential. Your information will be stored until study recruitment is closed. Should you no longer want this information to be provided in the aforementioned ways, please contact the study team directly.

Study teams can login to review submissions